Cases
Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM)
Securities Class Action
Overview
Overview
- Date:
- 5/31/2019
- Company Name:
- Bellicum Pharmaceuticals, Inc.
- Stock Symbol:
- BLCM
- Class Period:
- FROM 1/13/2015 TO 1/30/2018
- Status:
- Closed/Complete
NEW YORK, May 31, 2019 – Bragar Eagel & Squire, P.C. is investigating potential claims against certain officers and directors of Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM)
On February 6, 2018 a complaint was filed alleging that between January 13, 2015 and January 30, 2018, defendants made materially false and misleading statements regarding the company’s business, operational and compliance policies. Specifically, the complaint alleges that defendants made false and/or misleading statements and/or failed to disclose that: (1) a substantial undisclosed risk of encephalopathy was associated with the company’s lead product candidate BPX-501; and (2) as a result of the foregoing, Bellicum’s public statements were materially false and misleading at all relevant times.
If you purchased or otherwise acquired Bellicum shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.
On February 6, 2018 a complaint was filed alleging that between January 13, 2015 and January 30, 2018, defendants made materially false and misleading statements regarding the company’s business, operational and compliance policies. Specifically, the complaint alleges that defendants made false and/or misleading statements and/or failed to disclose that: (1) a substantial undisclosed risk of encephalopathy was associated with the company’s lead product candidate BPX-501; and (2) as a result of the foregoing, Bellicum’s public statements were materially false and misleading at all relevant times.
If you purchased or otherwise acquired Bellicum shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.